Physician profile
Christine Diane Hamolia
NPI 1902914856
$4,966.34
in general payments reported to CMS, 2019-2025
25 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 92% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $703 · 2023: $809 · 2024: $1,050 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.77 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.04 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $444.71 | 2021-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $436.83 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $357.88 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $293.55 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $290.36 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $279.58 | 2021-2024 | Trintellix |
| Corium, LLC | $244.21 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $232.41 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $227.88 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $217.40 | 2023-2025 | Auvelity |
| Alkermes, INC. | $203.34 | 2023-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $175.48 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $158.16 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.47 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $75.24 | 2024-2025 | Quviviq, Quviviq |
| Livanova USA, INC. | $56.08 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Tris Pharma INC | $37.76 | 2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $33.79 | 2021 | |
| Eisai INC. | $28.90 | 2021-2022 | |
| Almatica Pharma LLC | $17.04 | 2025 | Loreev Xr |
| Neos Therapeutics, Lp | $15.62 | 2025 | Exxua |
| Collegium Pharmaceutical, INC. | $15.34 | 2025 | Jornay Pm |
| Allergan, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Hamolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.